Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.62
-0.17-6.09%
At close: -
$2.50
-0.12-4.58%
After Hours: Apr 4, 5:56 PM EDT
Comments
Loading...
aTyr Pharma Analyst Ratings and Price Targets | NASDAQ:ATYR | Benzinga
aTyr Pharma Inc has a consensus price target of $18.6 based on the ratings of 6 analysts. The high is $35 issued by HC Wainwright & Co. on March 14, 2025. The low is $9 issued by Jefferies on September 5, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Leerink Partners, and HC Wainwright & Co. on March 14, 2025, February 18, 2025, and December 10, 2024, respectively. With an average price target of $28.67 between HC Wainwright & Co., Leerink Partners, and HC Wainwright & Co., there's an implied 1046.67% upside for aTyr Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Leerink Partners
Wells Fargo
Jefferies
RBC Capital
1calculated from analyst ratings
Analyst Ratings for aTyr Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/14/2025 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/18/2025 | Buy Now | 540% | Leerink Partners | Faisal Khurshid28% | → $16 | Initiates | → Outperform | Get Alert |
| 01/06/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal35% | — | Initiates | → Overweight | Get Alert |
| 12/10/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 10/04/2024 | Buy Now | 580% | Wells Fargo | Derek Archila56% | → $17 | Initiates | → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 260% | Jefferies | Roger Song30% | → $9 | Initiates | → Buy | Get Alert |
| 08/15/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | 540% | RBC Capital | Gregory Renza46% | $16 → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 08/01/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 1300% | HC Wainwright & Co. | Joseph Pantginis39% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for aTyr Pharma (ATYR) stock?
The latest price target for aTyr Pharma (NASDAQ:ATYR) was reported by HC Wainwright & Co. on March 14, 2025. The analyst firm set a price target for $35.00 expecting ATYR to rise to within 12 months (a possible 1300.00% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for aTyr Pharma (ATYR)?
The latest analyst rating for aTyr Pharma (NASDAQ:ATYR) was provided by HC Wainwright & Co., and aTyr Pharma reiterated their buy rating.
When was the last upgrade for aTyr Pharma (ATYR)?
There is no last upgrade for aTyr Pharma
When was the last downgrade for aTyr Pharma (ATYR)?
There is no last downgrade for aTyr Pharma.
When is the next analyst rating going to be posted or updated for aTyr Pharma (ATYR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
Is the Analyst Rating aTyr Pharma (ATYR) correct?
While ratings are subjective and will change, the latest aTyr Pharma (ATYR) rating was a reiterated with a price target of $35.00 to $35.00. The current price aTyr Pharma (ATYR) is trading at is $2.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.